M-M-R®II is indicated for simultaneous vaccination against measles, mumps, and rubella in individuals 12 months of age or older.
Selected Safety Information for
Due caution should be employed in administration of
The following adverse reactions have been reported with
As for any vaccine, vaccination with
|1.||Centers for Disease Control and Prevention (CDC). National Center for Immunization and Respiratory Diseases. Vaccine Storage & Handling Toolkit. http://www.cdc.gov/vaccines/recs/storage/toolkit/
storage-handling-toolkit.pdf. Published May 2014. Accessed February 29, 2016.
|2.||Centers for Disease Control and Prevention (CDC). Milestones in the history of vaccination. In: Hamborsky J, Kroger A, Wolfe S, eds. Epidemiology and Prevention of Vaccine-Preventable Diseases. 13th rev ed. Washington, DC: Public Health Foundation; 2015:ii–xi.|
|3.||Food and Drug Administration (FDA). Center for
Biologics Evaluation and Research (CBER). CBER clinical review of studies submitted in support of licensure of ProQuad™. http://www.fda.gov/downloads/
approvedproducts/ucm123800.pdf. Effective August 26, 2005. Accessed February 29, 2016.
|4.||Centers for Disease Control and Prevention (CDC). Recommended immunization schedules for persons aged 0 through 18 years—United States, 2016. http://www.cdc.gov/vaccines/schedules/downloads/
child/0-18yrs-child-combined-schedule.pdf. Effective January 1, 2016. Accessed February 29, 2016.